The present study investigated differences in PON1 and PON3 activities and serum MDA levels and lipid profile levels between patients with Pca, patients with benign prostatic hyperplasia (BPH) having previously undergone RALRP, and a control group. The gene discussed is PON1; the disease is posterior cortical atrophy.